Luspatercept Shows Long-Term Survival Benefit and Transfusion Independence After 3-Year Follow-Up

At the 2026 American Society of Clinical Oncology Annual Meeting, researchers shared updates from the phase 3 COMMANDS trial for people with lower-risk myelodysplastic syndrome (MDS). The research was led by Dr. Guillermo Garcia-Manero, an expert in MDS.

This new analysis brings more than three years of comprehensive follow-up data. Luspatercept provides a strong, long-term survival advantage and durable transfusion independence with luspatercept compared to the standard treatment, epoetin-alfa.

COMMANDS trial updates after three years

One of the main goals for lower-risk MDS is to become less dependent on blood transfusions. Because that would mean that the body can maintain healthy red blood cell counts on its own without requiring frequent blood donor transfusions. These transfusions can be disruptive and challenging for people with MDS.

The 3 year update provides important insights to what luspatercept may offer for patients with low-risk MDS:

Longer overall survival: Half of the patients taking the standard drug, epoetin alfa, had died by the 46-month mark. In contrast, more than half of the patients taking luspatercept were still alive at that point. This shows that luspatercept provides a steady, long-term survival advantage for all different types of patients in the study.

Nearly doubled the time free from transfusions: Earlier data showed that luspatercept helped more patients take an initial break from blood transfusions. The new three-year data show exactly how long that relief lasts. Patients on luspatercept went a median of 184.4 weeks (about 3.5 years) without needing a transfusion, compared to just 95.1 weeks (just under 2 years) for those on the standard drug. Additionally, about 1 in 4 luspatercept patients went at least 2.5 years completely transfusion-free, compared to only 1 in 10 epoetin alfa patients.

Longer-lasting blood quality improvements: Luspatercept did a better job of improving overall red blood cell quality. A helpful boost in hemoglobin (at least 1.5 g/dL), which raises blood oxygen levels, happened in 80.2% of luspatercept patients compared to 58.6% of epoetin alfa patients. Most importantly, this boost lasted a median of 72.9 weeks for those on luspatercept, compared to 47.9 weeks for the standard care group.

Researchers also found that biological markers indicators of favorable immune system health and strong cardiovascular function, were highly predictive of achieving the best overall survival outcomes on luspatercept.

What’s next for luspatercept 

These updated findings provide strong evidence for clinical benefits of luspatercept as a first-line treatment option for transfusion-dependent, lower-risk MDS patients who have not yet tried erythropoiesis-stimulating agents.

Consider discussing these long-term survival and durability trends with your medical team to see if initiating luspatercept aligns with your personal health and wellness goals.

SUBSCRIBE TO NEWSLETTER 

Source: Updated overall survival (OS) and long-term transfusion-independence (TI) from the phase 3 COMMANDS trial in erythropoiesis-stimulating agent (ESA)–naive patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).